Management of acute pulmonary exacerbations in cystic fibrosis: A critical appraisal

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Optimal management of acute exacerbations of pulmonary symptoms in patients with cystic fibrosis remains questionable. The underlying cause of such exacerbations has not been identified, and the microbiology of the sputum does not differ substantially during these exacerbations. Despite the absence of conclusive evidence that antibiotic therapy enhances treatment of cystic fibrosis, the consensus favors its use. Various combination and single-agent therapies with aminoglycosides, cephalosporins, and β-lactam antibiotics are reviewed critically. The importance of high activity against Pseudomonas strains is addressed, as is the potential value of antibiotic prophylaxis. The drawbacks of aminoglycoside treatment are reported. No evidence proves the superiority of combination therapy over monotherapy. Recent results suggesting the effectiveness of monotherapy with piperacillin or ceftazidime are encouraging and deserve follow-up to test continued efficacy and the absence of development of resistant antibiotic strains. Further investigation into the prevention of acute pulmonary exacerbations in cystic fibrosis is essential.

Original languageEnglish (US)
Pages (from-to)1030-1034
Number of pages5
JournalThe Journal of pediatrics
Issue number6
StatePublished - Jun 1985

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Management of acute pulmonary exacerbations in cystic fibrosis: A critical appraisal'. Together they form a unique fingerprint.

Cite this